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Epstein-Barr virus (EBV) genome has been detected in several human lymphoproliferative diseases, but the
oncogenic function of EBV is not fully understood. We previously established EBV-positive (SP-50B) and EBV-
negative (SP-53) cell lines with the t(11;14)(q13;q32) chromosome abnormality from a single patient with
mantle cell lymphoma. Monoclonal EBV DNA in a circular episomal form was demonstrated in the SP-50B
cells by Southern blot hybridization with the EBV-terminal fragment probe. SP-50B cells were positive for not
only EBV-encoded nuclear antigen-1 (EBNA1) but also latent membrane protein-1 and EBNA2. None of the
EBV-encoded proteins was expressed in SP-53 cells. The isogenic EBV-infected and EBV-free cell lines of
neoplastic clones made it possible to examine a tumorigenic role of EBV. Only EBV-positive SP-50B cells
possessed malignant phenotypes, such as growth ability in low serum, colony formation in soft agarose, and
tumorigenicity in nude mice. On the other hand, a lymphoblastoid B-cell line established by infecting the patient’s
normal B lymphocytes in vitro with exogenous EBV had no tumorigenicity. These results suggested that EBV
infection, if it occurred in neoplastic lymphoma cells, could play a role in acquisition of malignant phenotypes.
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus
which infects B lymphocytes and certain epithelial cells and is
implicated in several human malignancies, including Burkitt’s
lymphoma and nasopharyngeal carcinoma (18). Although
EBV infection was also detected in Hodgkin’s lymphoma (34,
35) and non-Hodgkin’s lymphoma, especially in immunosup-
pressed individuals (9, 17, 39), the oncogenic function of EBV
in these lymphoproliferative diseases is not well delineated.
Structural and functional alterations of oncogene loci in-
duced by chromosomal translocations are consistently found in
many hematopoietic malignancies and are implicated in tu-
morigenesis. Burkitt’s lymphomas (BLs), for example, are
characterized by specific reciprocal chromosomal transloca-
tions that involve the c-myc oncogene locus on chromosome
8q24 and various immunoglobulin gene loci on chromosome
14, 2, or 22, resulting in activation of the c-myc gene. While the
deregulation of the c-myc gene is thought to play a pathoge-
netic role in BL, in the case of EBV-positive BL, EBV infec-
tion is also considered as an additional pathogenetic element.
Recently, Shimizu et al. isolated EBV-positive and EBV-neg-
ative clones in vitro from a t(8;14)(q24;q32)-carrying BL cell
line which was originally 100% positive for EBV and demon-
strated that only the EBV-positive clone exhibits tumorigenic-
ity (28). On the other hand, EBV-infected human B lympho-
blastoid cells acquired tumorigenicity when transfected with
constitutively expressed c-myc gene (16). These results suggest
that both EBV infection and c-myc activation are necessary for
acquisition of tumorigenicity in endemic BL. Thus, while sev-
eral studies to explore tumorigenesis of BL in conjunction with
EBV infection and c-myc gene activation have been reported,
the tumorigenic role of EBV in other non-Hodgkin’s lympho-
mas has not been well investigated, possibly because of the lack
of ideal model systems.
Mantle cell lymphoma (also called intermediate lymphocytic
lymphoma) is a form of intermediate-grade non-Hodgkin’s
lymphoma that originates from mature B cells in the primary
follicle and mantle zone of peripheral lymphoid organs (3, 12,
31). The chromosome translocation t(11;14)(q13;q32) is char-
acteristic of mantle cell lymphoma and occurs in up to 70% of
the cases (4, 23, 24, 37). As a result of t(11;14)(q13;q32) chro-
mosome translocation, the bcl-1 locus on chromosome 11q13 is
juxtaposed to an immunoglobulin heavy chain gene on chro-
mosome 14. The subsequent deregulation of the cyclin D1/
PRAD1 oncogene, a member of the cyclin G1 gene family, is
considered to contribute to tumorigenicity (11, 20, 24).
We previously established EBV-positive (SP-50B) and EBV-
negative (SP-53) cell lines from a single patient with mantle
cell lymphoma (7). The paired availability of the EBV-infected
and EBV-free cell lines of neoplastic clones with the same
origin is valuable in the investigation of the tumorigenic role of
EBV.
Both the SP-50B and SP-53 cells had the same phenotypic
markers as original lymphoma cells in respect of surface and
cytoplasmic immunoglobulins and other cell markers, such as
CD5, CD10, and CD19 (7). They possessed the t(11;14)(q13;
q32) chromosome translocation, indicating that these cell lines
were derived from the original lymphoma cells. Molecular
analyses revealed a rearrangement of the cyclin D1/PRAD1
gene in both cell lines (26). Thus, SP-50B and SP-53 cells had
similar characteristics except for EBV infection. We had also
attempted to infect the EBV-negative SP-53 cells in vitro with
exogenous EBV by incubating the cells in the supernatant of
the B95-8 cell line, but it was unsuccessful (7). A third cell line
derived from the same patient, SP-52EB, was established by
infecting the peripheral blood cells with the B95-8 virus and
had no chromosome abnormality (7). SP-52EB is considered to
be a lymphoblastoid cell line (LCL) originated from normal B
lymphocytes. These cell lines had been preserved in liquid
nitrogen, and each cell line within the 30th passage was used in
this study. EBV infection in these cell lines was further con-
firmed by examining for the presence of EBV-encoded small
RNA (EBER) by the in situ hybridization method. SP-50B and
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SP-52EB cells were strongly positive for EBER, as expected,
whereas none of the SP-53 cells expressed EBER, confirming
that SP-53 is an EBV-free cell line (data not shown). Immu-
noblot analysis demonstrated that both SP-50B and SP-52EB
cells were positive for not only EBNA1 but also LMP1 and
EBNA2 (Fig. 1). This pattern of viral gene expression was
similar to that observed in some cases of EBV-associated B-
cell lymphoproliferative diseases and in EBV-infected LCL,
where a full set of latent EBV genes is expressed (8, 38). We
next tested clonality of EBV in the SP-50B and SP-52EB cells
by Southern blot hybridization analysis using the EBV-termi-
nal fragment probe (22). A major single band was demon-
strated at 12 kb in DNA from SP-50B cells, indicating that the
viral DNA was monoclonal in a circular episomal form with
fused termini, whereas EBV DNA from SP-52EB cells showed
multiple bands between 14 and 8 kb, representing polyclonal
EBV infection (Fig. 2).
The growth ability of each cell line was tested in RPMI 1640
medium containing only 0.1% fetal calf serum (FCS) (GIBCO
BRL, Gaithersburg, Md.) at the initial cell concentration of
4 3 105/ml. Representative results from two independent ex-
periments are shown in Fig. 3. SP-50B cells showed continuous
growth and reached the maximum cell density at around 106
cells per ml at 3 days. Thereafter, the number of viable cells
decreased, but some cells still survived over a period of 7 days
in 0.1% FCS. In contrast, SP-53 cells showed no increase in cell
number over the first 2 days and then gradually lost viability.
Almost all cells died after 7-day culture. The growth curve of
SP-52EB cells was similar to that of SP-53 cells.
The growth properties of these three cell lines were also
studied by examining their ability to form colonies in soft
agarose (Fig. 4A). SP-50B cells formed visible colonies 7 to 14
days after plating, while SP-53 and SP-52EB cells did not form
colonies under the same conditions. A group of more than 20
viable cells was scored as a clone 14 days following seeding.
The cloning efficiency of the SP-50B cells from the average of
three experiments was 27.2%.
We next tested the ability of the cell lines to form tumors in
vivo when injected subcutaneously into 4- to 5-week-old athy-
mic nude mice. SP-50B cells gave rise to tumors with a high
take incidence at all inoculum doses tested (Table 1). The
palpable subcutaneous nodules (0.5-cm diameter) could usu-
ally be detected within 2 weeks after inoculation of 0.5 3 107
to 1 3 107 SP-50B cells and progressed to apparent tumors
with no sign of regression or necrosis (Fig. 4B). In comparison
with SP-50B cells, SP-53 cells exhibited a considerably lower
tumorigenicity. Even with 5 3 107 cells, the SP-53 cells failed
to yield any detectable tumors. The minimum inoculum dose
of the SP-53 cells capable of producing a tumor was 108 cells in
this system, and the tumor appeared in only one of four mice
inoculated with this dose. Likewise, SP-52EB had no tumori-
genicity. When 0.5 3 108 to 1 3 108 SP-52EB cells were
inoculated, small nodules were occasionally observed within 2
weeks, but this was followed by complete regression within
another 2 weeks. The nude mouse tumor cells were positive for
EBNA1, as well as EBNA2 and LMP1, and monoclonal EBV
FIG. 1. Immunoblot analysis of EBV-encoded proteins. Proteins (corresponding to 3 3 105 cells) were subjected to sodium dodecyl sulfate–10% polyacrylamide
gel electrophoresis and transferred onto a nitrocellulose filter as described previously (6). The proteins were reacted with a polyclonal antibody specific to EBNA1 (A),
with anti-LMP1 monoclonal antibody CS1-4 (25) (B), or with anti-EBNA2 monoclonal antibody PE2 (38) (C); this was followed by incubation with peroxidase-labeled
protein A or anti-mouse antibody. The blots were developed by the enhanced chemiluminescence method. EBNA1, LMP1, and EBNA2 bands are indicated by arrows.
Positions of mass markers are indicated on the left. Lanes 1, SP-50B; lanes 2, SP-53; lanes 3, SP-52EB.
FIG. 2. Clonality analysis of EBV genomes. Total cellular DNAs were di-
gested with BamHI, subjected to electrophoresis through a 0.75% agarose gel,
transferred onto a nylon membrane filter, and hybridized to the 32P-labeled XhoI
fragments that represent unique sequences at the right end of the EBV genome.
Raji has a monoclonal EBV DNA in an episomal form. B95-8 shows polyclonal
EBV infection with linear DNA. Positions of size markers are shown on the left.
Lane 1, SP-50B; lane 2, SP-53; lane 3, SP-52EB.
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DNA was demonstrated (data not shown). Chromosome anal-
ysis showed that the tumor cells had a human karyotype con-
taining the t(11;14)(q13;q32) chromosome abnormality (data
not shown). These results confirmed that the tumors were
derived from in vivo growth of the injected SP-50B cells.
In the present study, we have performed a comparative study
of tumorigenicity between SP-50B and SP-53 lymphoma cell
lines having similar characteristics except for EBV infection.
The results are summarized in Table 2. SP-50B cells exhibited
a far higher tumorigenicity than SP-53 cells, as shown by
growth ability in low serum, clonogenicity in soft agarose, and
tumorigenicity in nude mice. Neither of the SP-53 and SP-
52EB lines grew in soft agarose nor did they produce progres-
sively growing tumors in nude mice. The molecular events in
the acquisition of the malignant phenotypes of EBV-infected
lymphoma cells are poorly understood. The immortalizing
function of EBV infection itself seems not to be associated
with tumorigenic capabilities, as suggested by the evidence that
the EBV-infected SP-52EB LCL showed no tumorigenicity.
Other pathogenetic events, in addition to EBV infection, are
likely to be involved in the higher tumorigenesis of SP-50B
cells.
Deregulated cellular oncogenes induced by abnormal chro-
mosomal rearrangements are known to correlate with tumor
progression and tumorigenesis. The most well-characterized
oncogene in conjunction with EBV is c-myc, associated with
t(8;14)(q24;q32) in BL. Several studies indicated that the c-myc
activation and EBV infection cooperatively play a tumorigenic
role in BL. The expression of an activated c-myc gene caused
the tumorigenic conversion of normal EBV-infected LCL (5,
16), and conversion of an EBV-negative BL line (BJAB) to a
permanently EBV-carrying subline led to acquisition of tumor-
igenic capabilities by increasing the level of c-myc expression
(14, 15, 36). Furthermore, additional evidence comes from a
recent study that the presence of the EBV genome was indis-
pensable for the sustenance of malignant phenotypes of BL, as
concluded by a comparative study with EBV-positive and
EBV-negative BL clones (28). The expression of c-myc gene
was examined in tumorigenic SP-50B and nontumorigenic
SP-53 lines by Northern (RNA) blot analysis. The c-myc gene
was expressed at similar levels in both cell lines, indicating that
FIG. 3. Growth curves of SP-50B (open circles), SP-53 (solid circles), and
SP-52EB cells (open squares) in 0.1% FCS after resuspension at a density of 4 3
105 cells per ml. Cell proliferation was monitored daily for 7 days. The number
of viable cells was counted by the trypan blue-dye exclusion method.
FIG. 4. (A) Growth of SP-50B cells in soft agarose. One thousand cells
suspended in medium containing 0.3% agarose (Sea Plaque; FMC BioProduct,
Rockland, Maine) were layered onto an underlayer formed by 0.5% agarose in
medium. A colony formation was photographed under an inverted microscope 14
days following seeding. (B) A nude mouse bearing a tumor initiated by an
injection with SP-50B cells. The nude mouse was photographed 8 weeks after
inoculation with 5 3 106 cells.
TABLE 1. Tumorigenicity assay in nude micea
No. of
cells
inoculated
No. of mice with tumors/no. of mice inoculated
SP-50B SP-53 SP-52EB
5 3 106 3/4 NDb ND
1 3 107 3/3 0/3 0/3
5 3 107 3/3 0/3 0/3
1 3 108 3/3 1/4 0/3
a Four-to-five-week-old nude mice were inoculated subcutaneously with vari-
ous numbers of cells. Data are the number of mice with tumors 8 weeks after
inoculation.
b ND, not done.
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the difference in tumorigenicity between SP-50B and SP-53
lines was not due to activation of the c-myc gene (data not
shown).
The t(11;14)(q13;q32) chromosomal translocation in mantle
cell lymphoma is considered to be structurally similar to the
t(8;14)(q24;q32) in BL. The deregulated expression of the cy-
clin D1 oncogene is thought to be a critical step in tumorigen-
esis in mantle cell lymphoma (11, 20, 24). Having demon-
strated that SP-53 cells had little tumorigenesis, it is unlikely
that the presence of the t(11;14)(q13;q32) alone is sufficient for
the potentiation of malignancy. It is hypothesized, therefore,
that the EBV gene product(s) might further regulate the func-
tion of the already overexpressed cyclin D1 oncogene directly
or indirectly, and that this might be related to the stronger
tumorigenicity of the SP-50B cells. Rearrangement of the cy-
clin D1 gene in both SP-50B and SP-53 cells was already
confirmed, while no rearrangement was observed in SP-52EB
cells (26). Further comparative studies including cyclin D1
protein analysis will be needed to better understand the mech-
anisms responsible for the difference of tumorigenicity of these
cell lines.
SP-50B cells expressed LMP1 and EBNA2. These EBV-
encoded proteins are essential for the growth transformation
and immortalization of B lymphocytes. LMP1 upregulates
bcl-2 oncogene, which renders B lymphocytes resistant to ap-
optotic death (10). Recently, Mosialos et al. demonstrated that
LMP1 interacts with tumor necrosis factor receptor-associated
factor leading to activation of NF-kB, which is likely to be
relevant to the growth transformation function of LMP1 (19).
EBNA2 induces transactivation of the cellular oncogene c-fgr
and, in combination with LMP1, transactivates bcl-2 (1, 13, 33).
Both LMP1 and EBNA2 are considered to be associated with
tumorigenicity, since transfection of transcriptionally active
gene constructs into rodent fibroblasts resulted in acquisition
of malignant phenotypes, including growth ability in low se-
rum, colony formation in soft agarose, and tumor formation in
nude mice (27, 32). But, the tumorigenic role of LMP1 and
EBNA2 in human lymphoma cells is still unclear. Recently, it
was reported that expression of cyclin D2, another member of
the cyclin G1 gene family, was induced by LMP1 and EBNA2
(2, 29, 30). The findings imply that expression of the cyclin D2
following EBV infection subverts the cell cycle control and
thereby leads to uncontrolled cell proliferation. On the other
hand, cyclin D1 is usually undetectable in EBV-infected BL
lines and LCLs (21). In this context, it would be interesting to
examine whether or how EBV infection in t(11;14)(q13;q32)-
carrying lymphoma cells affects the constitutively expressed
cyclin D1 oncogene.
In summary, by utilizing the isogenic EBV-positive and -neg-
ative lymphoma cell lines, which are, to our knowledge, the
first cell lines available from mantle cell lymphoma, we have
successfully demonstrated the putative role of EBV in acqui-
sition of malignant phenotypes of other non-Hodgkin’s lym-
phoma besides BL.
We thank S. Imai for the gift of EBV XhoI probe. We are also
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